Identification

Name
BL-1020
Accession Number
DB05687
Type
Small Molecule
Groups
Investigational
Description

BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).

Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in schizophrenia and schizoaffective disorders.

Pharmacodynamics

Extensive preclinical testing of BL-1020 has shown it to have a positive safety and pharmacokinetic profile. BL-1020 reduces dopamine activity while avoiding the side affects associated with unmitigated dopamine blockade. In animal models of schizophrenia, BL-1020 reduces behaviors characteristic of psychosis and causes minimal or no impairment of movement, the most severe side effect of classic antipsychotic drugs. Biochemical testing confirms that BL-1020 works via the mechanism previously established for classic antipsychotics. BL-1020 is structurally and mechanistically distinct from the atypical antipsychotics and is not anticipated to trigger diabetes or elevated cholesterol. Preliminary studies do not reveal toxicity.

Mechanism of action

In radioligand binding studies, BL-1020 displayed strong interaction with dopamine receptors especially D2L and D2S (Ki of 0.27 nM and 0.17 nM respectively), the serotonin receptor 5-HY2a (Ki 0.25 nM) as well as moderate interaction with the GABAA receptor (Ki 3.29 microK).

TargetActionsOrganism
UD(2) dopamine receptorNot AvailableHuman
U5-hydroxytryptamine receptor 2ANot AvailableHuman
Absorption

Orally available.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

BL-1020, after oral administration, crosses the blood brain barrier intact and is metabolized to GABA and perphenazine.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of BL-1020 can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
AcebutololBL-1020 may increase the hypotensive activities of Acebutolol.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when BL-1020 is combined with Alaproclate.Experimental
AlfentanilBL-1020 may increase the hypotensive activities of Alfentanil.Approved, Illicit
AlmasilateAlmasilate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlphacetylmethadolBL-1020 may increase the hypotensive activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineBL-1020 may increase the hypotensive activities of Alphaprodine.Illicit
AlprenololBL-1020 may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when BL-1020 is combined with Amikacin.Approved, Investigational, Vet Approved
AmodiaquineThe serum concentration of BL-1020 can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Amoxapine.Approved
ArotinololBL-1020 may increase the hypotensive activities of Arotinolol.Investigational
ArtemetherThe serum concentration of BL-1020 can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of BL-1020 can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of BL-1020 can be increased when it is combined with Artemotil.Approved
ArtenimolThe serum concentration of BL-1020 can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of BL-1020 can be increased when it is combined with Artesunate.Approved, Investigational
AsenapineBL-1020 may increase the hypotensive activities of Asenapine.Approved
AtenololBL-1020 may increase the hypotensive activities of Atenolol.Approved
AtovaquoneThe serum concentration of BL-1020 can be increased when it is combined with Atovaquone.Approved
BefunololBL-1020 may increase the hypotensive activities of Befunolol.Experimental
BenzphetamineBL-1020 may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with BL-1020.Approved
BetaxololBL-1020 may increase the hypotensive activities of Betaxolol.Approved, Investigational
BevantololBL-1020 may increase the hypotensive activities of Bevantolol.Approved
BezitramideBL-1020 may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololBL-1020 may increase the hypotensive activities of Bisoprolol.Approved
BopindololBL-1020 may increase the hypotensive activities of Bopindolol.Approved
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with BL-1020.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with BL-1020.Approved
BucindololBL-1020 may increase the hypotensive activities of Bucindolol.Investigational
BufuralolBL-1020 may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupranololBL-1020 may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineBL-1020 may increase the hypotensive activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with BL-1020.Approved
ButorphanolBL-1020 may increase the hypotensive activities of Butorphanol.Approved, Illicit, Vet Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with BL-1020.Approved, Investigational
CarfentanilBL-1020 may increase the hypotensive activities of Carfentanil.Illicit, Investigational, Vet Approved
CarteololBL-1020 may increase the hypotensive activities of Carteolol.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with BL-1020.Approved, Investigational
CeliprololBL-1020 may increase the hypotensive activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with BL-1020.Approved
ChloroquineThe serum concentration of BL-1020 can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with BL-1020.Approved
ChlorproguanilThe serum concentration of BL-1020 can be increased when it is combined with Chlorproguanil.Investigational
CitalopramThe risk or severity of adverse effects can be increased when BL-1020 is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with BL-1020.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when BL-1020 is combined with Clindamycin.Approved, Vet Approved
ClomipramineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Clomipramine.Approved, Investigational, Vet Approved
CloranololBL-1020 may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of hypotension and central nervous system depression can be increased when BL-1020 is combined with Codeine.Approved, Illicit
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with BL-1020.Approved
Cycloguanil embonateThe serum concentration of BL-1020 can be increased when it is combined with Cycloguanil embonate.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Cyclosporine.Approved, Investigational, Vet Approved
DapoxetineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of BL-1020 can be increased when it is combined with Dapsone.Approved, Investigational
DesipramineBL-1020 may increase the hypotensive activities of Desipramine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Desvenlafaxine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with BL-1020.Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with BL-1020.Approved
DextromoramideBL-1020 may increase the hypotensive activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneBL-1020 may increase the hypotensive activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineBL-1020 may increase the hypotensive activities of Dezocine.Approved, Investigational
DiethylpropionBL-1020 may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DihydrocodeineBL-1020 may increase the hypotensive activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineBL-1020 may increase the hypotensive activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineBL-1020 may increase the hypotensive activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with BL-1020.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with BL-1020.Approved, Investigational
DiphenoxylateBL-1020 may increase the hypotensive activities of Diphenoxylate.Approved, Illicit
DotarizineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Dotarizine.Investigational
DoxycyclineThe serum concentration of BL-1020 can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of BL-1020.Approved, Vet Approved
DPDPEBL-1020 may increase the hypotensive activities of DPDPE.Experimental
EpanololBL-1020 may increase the hypotensive activities of Epanolol.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with BL-1020.Approved, Investigational
EsatenololBL-1020 may increase the hypotensive activities of Esatenolol.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when BL-1020 is combined with Escitalopram.Approved, Investigational
EsmololBL-1020 may increase the hypotensive activities of Esmolol.Approved
EthanolBL-1020 may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with BL-1020.Approved
EthylmorphineBL-1020 may increase the hypotensive activities of Ethylmorphine.Approved, Illicit
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with BL-1020.Approved
EtorphineBL-1020 may increase the hypotensive activities of Etorphine.Illicit, Vet Approved
FenfluramineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of hypotension and central nervous system depression can be increased when BL-1020 is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with BL-1020.Approved
FluoxetineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Fluoxetine.Approved, Vet Approved
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with BL-1020.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with BL-1020.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Fluvoxamine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with BL-1020.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with BL-1020.Approved, Investigational
HalofantrineThe serum concentration of BL-1020 can be increased when it is combined with Halofantrine.Approved
HeroinBL-1020 may increase the hypotensive activities of Heroin.Approved, Illicit, Investigational
HydrocodoneBL-1020 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneBL-1020 may increase the hypotensive activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxychloroquineThe serum concentration of BL-1020 can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of BL-1020.Approved
IndalpineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Indalpine.Investigational, Withdrawn
IndenololBL-1020 may increase the hypotensive activities of Indenolol.Withdrawn
KetobemidoneBL-1020 may increase the hypotensive activities of Ketobemidone.Approved, Investigational
LabetalolThe serum concentration of Labetalol can be increased when it is combined with BL-1020.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with BL-1020.Approved, Investigational
LandiololBL-1020 may increase the hypotensive activities of Landiolol.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with BL-1020.Approved, Investigational
LevobetaxololBL-1020 may increase the hypotensive activities of Levobetaxolol.Approved, Investigational
LevobunololBL-1020 may increase the hypotensive activities of Levobunolol.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with BL-1020.Approved
Levomethadyl AcetateBL-1020 may increase the hypotensive activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when BL-1020 is combined with Levomilnacipran.Approved, Investigational
LevorphanolBL-1020 may increase the hypotensive activities of Levorphanol.Approved
LofentanilBL-1020 may increase the hypotensive activities of Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with BL-1020.Approved, Investigational
LumefantrineThe serum concentration of BL-1020 can be increased when it is combined with Lumefantrine.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when BL-1020 is combined with Magnesium citrate.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateThe therapeutic efficacy of BL-1020 can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with BL-1020.Approved
MefloquineThe serum concentration of BL-1020 can be increased when it is combined with Mefloquine.Approved, Investigational
MepindololBL-1020 may increase the hypotensive activities of Mepindolol.Experimental
MeptazinolBL-1020 may increase the hypotensive activities of Meptazinol.Experimental
MethadoneBL-1020 may increase the hypotensive activities of Methadone.Approved
Methadyl AcetateBL-1020 may increase the hypotensive activities of Methadyl Acetate.Approved, Illicit
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with BL-1020.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when BL-1020 is combined with Methylphenidate.Approved, Investigational
MetipranololBL-1020 may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with BL-1020.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with BL-1020.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when BL-1020 is combined with Milnacipran.Approved, Investigational
MizoribineThe serum concentration of BL-1020 can be increased when it is combined with Mizoribine.Investigational
MorphineBL-1020 may increase the hypotensive activities of Morphine.Approved, Investigational
NadololBL-1020 may increase the hypotensive activities of Nadolol.Approved
NalbuphineBL-1020 may increase the hypotensive activities of Nalbuphine.Approved
NebivololBL-1020 may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when BL-1020 is combined with Nefazodone.Approved, Withdrawn
NeomycinThe risk or severity of adverse effects can be increased when BL-1020 is combined with Neomycin.Approved, Vet Approved
NicomorphineBL-1020 may increase the hypotensive activities of Nicomorphine.Experimental
NormethadoneBL-1020 may increase the hypotensive activities of Normethadone.Approved, Illicit
OlanzapineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Olanzapine.Approved, Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with BL-1020.Approved
OpiumBL-1020 may increase the hypotensive activities of Opium.Approved, Illicit
OxprenololBL-1020 may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of hypotension and central nervous system depression can be increased when BL-1020 is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of hypotension and central nervous system depression can be increased when BL-1020 is combined with Oxymorphone.Approved, Investigational, Vet Approved
ParomomycinThe risk or severity of adverse effects can be increased when BL-1020 is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Paroxetine.Approved, Investigational
PenbutololBL-1020 may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with BL-1020.Experimental
PentazocineBL-1020 may increase the hypotensive activities of Pentazocine.Approved, Vet Approved
PethidineBL-1020 may increase the hypotensive activities of Pethidine.Approved
PhenazocineBL-1020 may increase the hypotensive activities of Phenazocine.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with BL-1020.Approved, Investigational
PhenoperidineBL-1020 may increase the hypotensive activities of Phenoperidine.Experimental
PindololBL-1020 may increase the hypotensive activities of Pindolol.Approved, Investigational
PiperaquineThe serum concentration of BL-1020 can be increased when it is combined with Piperaquine.Approved, Investigational
PiritramideBL-1020 may increase the hypotensive activities of Piritramide.Approved, Investigational
Platelet Activating FactorBL-1020 may increase the hypotensive activities of Platelet Activating Factor.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when BL-1020 is combined with Polymyxin B Sulfate.Approved, Vet Approved
PractololBL-1020 may increase the hypotensive activities of Practolol.Approved
PramipexoleBL-1020 may increase the sedative activities of Pramipexole.Approved, Investigational
PregabalinThe therapeutic efficacy of BL-1020 can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrimaquineThe serum concentration of BL-1020 can be increased when it is combined with Primaquine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with BL-1020.Approved, Vet Approved
ProguanilThe serum concentration of BL-1020 can be increased when it is combined with Proguanil.Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with BL-1020.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with BL-1020.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with BL-1020.Approved, Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with BL-1020.Approved
PyrantelThe risk or severity of adverse effects can be increased when Pyrantel is combined with BL-1020.Approved, Vet Approved
PyrimethamineThe serum concentration of BL-1020 can be increased when it is combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyronaridineThe serum concentration of BL-1020 can be increased when it is combined with Pyronaridine.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with BL-1020.Approved
QuinacrineThe serum concentration of BL-1020 can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidineThe serum concentration of BL-1020 can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of BL-1020 can be increased when it is combined with Quinine.Approved
RadicicolThe serum concentration of BL-1020 can be increased when it is combined with Radicicol.Experimental
RemifentanilBL-1020 may increase the hypotensive activities of Remifentanil.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with BL-1020.Approved
RopiniroleBL-1020 may increase the sedative activities of Ropinirole.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with BL-1020.Approved, Investigational
SertralineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Sertraline.Approved
SinefunginThe serum concentration of BL-1020 can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolBL-1020 may increase the hypotensive activities of Sotalol.Approved
SufentanilBL-1020 may increase the hypotensive activities of Sufentanil.Approved, Investigational
SulfadoxineThe serum concentration of BL-1020 can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of BL-1020 can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with BL-1020.Approved, Investigational
TafenoquineThe serum concentration of BL-1020 can be increased when it is combined with Tafenoquine.Approved, Investigational
TalinololBL-1020 may increase the hypotensive activities of Talinolol.Investigational
TapentadolBL-1020 may increase the hypotensive activities of Tapentadol.Approved
TerbutalineBL-1020 may increase the hypotensive activities of Terbutaline.Approved
TertatololBL-1020 may increase the hypotensive activities of Tertatolol.Experimental
TetracyclineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with BL-1020.Investigational
TetrandrineThe risk or severity of QTc prolongation can be increased when Tetrandrine is combined with BL-1020.Experimental
ThiopentalThe risk or severity of adverse effects can be increased when BL-1020 is combined with Thiopental.Approved, Vet Approved
TilidineBL-1020 may increase the hypotensive activities of Tilidine.Experimental
TimololBL-1020 may increase the hypotensive activities of Timolol.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with BL-1020.Approved
TramadolThe risk or severity of hypotension and central nervous system depression can be increased when BL-1020 is combined with Tramadol.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when BL-1020 is combined with Trazodone.Approved, Investigational
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with BL-1020.Approved
TrimethoprimThe serum concentration of BL-1020 can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TromethamineTromethamine can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with BL-1020.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when BL-1020 is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with BL-1020.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Venlafaxine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when BL-1020 is combined with Vilazodone.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with BL-1020.Investigational
VortioxetineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Vortioxetine.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with BL-1020.Approved
ZimelidineThe risk or severity of adverse effects can be increased when BL-1020 is combined with Zimelidine.Withdrawn
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with BL-1020.Approved, Investigational
ZolpidemBL-1020 may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with BL-1020.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910192
Wikipedia
BL-1020

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
2CompletedTreatmentSchizophrenic Disorders1
2, 3TerminatedTreatmentCognitive Effect on Schizophrenic Patients / Schizophrenic Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da

Drug created on November 18, 2007 11:27 / Updated on August 02, 2018 05:32